BDSX vs. FLGT, CELC, SERA, BNR, PSNL, ENZ, XGN, RNLX, PMD, and DMTK
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Fulgent Genetics (FLGT), Celcuity (CELC), Sera Prognostics (SERA), Burning Rock Biotech (BNR), Personalis (PSNL), Enzo Biochem (ENZ), Exagen (XGN), Renalytix (RNLX), Psychemedics (PMD), and DermTech (DMTK). These companies are all part of the "medical laboratories" industry.
Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.
In the previous week, Fulgent Genetics had 1 more articles in the media than Biodesix. MarketBeat recorded 4 mentions for Fulgent Genetics and 3 mentions for Biodesix. Biodesix's average media sentiment score of 1.36 beat Fulgent Genetics' score of 1.15 indicating that Fulgent Genetics is being referred to more favorably in the media.
Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
Fulgent Genetics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.
48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 32.7% of Fulgent Genetics shares are owned by insiders. Comparatively, 69.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Fulgent Genetics received 217 more outperform votes than Biodesix when rated by MarketBeat users. However, 72.97% of users gave Biodesix an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
Fulgent Genetics has a net margin of -57.72% compared to Fulgent Genetics' net margin of -85.80%. Biodesix's return on equity of -2.92% beat Fulgent Genetics' return on equity.
Fulgent Genetics currently has a consensus price target of $30.00, indicating a potential upside of 38.76%. Biodesix has a consensus price target of $3.10, indicating a potential upside of 113.79%. Given Fulgent Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Fulgent Genetics.
Summary
Fulgent Genetics and Biodesix tied by winning 9 of the 18 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
